ASTELLAS PHARMA
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients
- Conditions
- First Posted Date
- 2003-11-07
- Last Posted Date
- 2011-10-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 52
- Registration Number
- NCT00072618
- Locations
- 🇺🇸
University of Colorado Health Sciences Center, Aurora, Colorado, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2003-07-14
- Last Posted Date
- 2013-12-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 668
- Registration Number
- NCT00064701
CP-461 in the Treatment of Patients With Advanced Melanoma
- Conditions
- First Posted Date
- 2003-05-13
- Last Posted Date
- 2011-10-17
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 35
- Registration Number
- NCT00060710
- Locations
- 🇺🇸
Columbia Presbyterian Medical Center, New York, New York, United States
YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer
- Conditions
- First Posted Date
- 2002-12-04
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Astellas Pharma Inc
- Registration Number
- NCT00050297
- Locations
- 🇪🇸
Complejo Hospitaliaro Juan Canalejo, Servicio de Urología, Corunna, Spain
🇵🇱MedSource Poland, Gdansk, Poland
🇵🇱Bielanski Hospital, Department of Urology, Warszawa, Poland
Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU
- First Posted Date
- 2002-11-08
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 104
- Registration Number
- NCT00048750
YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
- Conditions
- First Posted Date
- 2002-11-06
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Astellas Pharma Inc
- Registration Number
- NCT00048659
- Locations
- 🇺🇸
Michiana Hematology/Oncology, South Bend, Indiana, United States
🇫🇷Centre Paul Papin, Angers, France
🇩🇪Dept Urology University of Essen, Essen, Germany
Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis
- First Posted Date
- 2002-10-24
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 2
- Registration Number
- NCT00047827
Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection
- Conditions
- First Posted Date
- 2002-10-24
- Last Posted Date
- 2011-12-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 48
- Registration Number
- NCT00047814
- Locations
- 🇺🇸
University of Florida and Shands Hospital, Gainsville, Florida, United States
🇺🇸Rocky Mount Gastroenterology, Lakewood, Colorado, United States
🇺🇸Liver Center Huntington Memorial Hospital, Pasadena, California, United States
Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer
- Conditions
- First Posted Date
- 2002-10-04
- Last Posted Date
- 2011-10-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 80
- Registration Number
- NCT00046800
- Locations
- 🇺🇸
The Sarah Cannon Cancer Center, Centennial Medical Center, Nashville, Tennessee, United States
🇺🇸NYU- Kaplan Comprehensive Cancer Center, New York, New York, United States
🇬🇧St Chad's Unit, Birmingham, United Kingdom
Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2002-10-04
- Last Posted Date
- 2011-10-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 47
- Registration Number
- NCT00046787
- Locations
- 🇬🇧
Christie Hospital, Manchester, United Kingdom
🇺🇸Vanderbilt Clinical Trials Office, Nashville, Tennessee, United States
🇺🇸University of Colorado Health Sciences Center, Denver, Colorado, United States